GF Fund Management’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.94K Buy
2,269
+185
+9% +$470 ﹤0.01% 568
2026
Q2
$4.96K Sell
2,084
-158
-7% -$435 ﹤0.01% 572
2026
Q1
$6.17K Buy
2,242
+270
+14% +$838 ﹤0.01% 594
2025
Q4
$6.19K Sell
1,972
-188
-9% -$593 ﹤0.01% 611
2025
Q3
$6.24K Sell
2,160
-294
-12% -$664 ﹤0.01% 595
2025
Q2
$4.98K Hold
2,454
– – ﹤0.01% 625
2025
Q1
$4.59K Buy
2,454
+377
+18% +$950 ﹤0.01% 627
2024
Q4
$5.61K Buy
+2,077
New +$6.49K ﹤0.01% 604

Other funds holding ACIU

GF Fund Management's ACIU Position: Q3 2026 in Review

GF Fund Management increased its AC Immune (ACIU) stake by 8.9% in Q3 2026, buying an estimated $470 and bringing the position to 2,269 shares worth $5.94K. The position accounts for ﹤0.01% of the portfolio, ranked #568.

GF Fund Management first reported a position in ACIU in Q4 2024 and has held it in 8 quarters since. The position peaked at $6.24K in Q3 2025. 9 funds tracked by Wall St. Rank hold ACIU as of Q3 2026.

  • GF Fund Management held 2,269 shares of AC Immune worth $5.94K as of Q3 2026.
  • GF Fund Management bought 185 AC Immune shares in Q3 2026, an estimated $470.
  • AC Immune made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #568 holding.
  • GF Fund Management first reported a position in AC Immune in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's AC Immune position peaked at $6.24K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held AC Immune as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.